Skip to main content
. 2017 Dec 8;2017(1):489–497. doi: 10.1182/asheducation-2017.1.489

Figure 3.

Figure 3.

Dynamic assessment of considerations for intervention in those with either PMF or sMF in 2017. EPO, erythropoietin; ESA, erythroid-stimulating agent; HLA, human leukocyte antigen; PET, postessential thrombocythemia; PPV postpolycythemia vera.